Literature DB >> 32322958

Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population.

Natalia Kirsten1, Nicole Zander2, Matthias Augustin2.   

Abstract

The association of hidradenitis suppurativa with other skin diseases has not yet been investigated in larger studies based on dermatological exams. The objectives of this study are to determine the prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Between 2014 and 2017, 20,112 people in 343 German companies were examined for the presence of clinical features of hidradenitis suppurativa within the framework of a cross-sectional epidemiological study based on whole-body examinations. In addition, all cutaneous comorbidities were recorded. Point prevalence was calculated and the differences between individuals with and without hidradenitis suppurativa were determined by bivariate analysis. All statistical procedures were performed using SPSS 23.0 for Windows. Of 20,112 people examined, mean age was 43.6 ± 10.5 years; 52.3% were male. In total, n = 57 people (0.3%) with hidradenitis suppurativa were identified; 61.4% (n = 35) being male. In addition, non-inflammatory hidradenitis suppurativa-related lesions were found in 674 other individuals. In a bivariate comparison, patients with hidradenitis suppurativa showed significantly more frequently the following cutaneous comorbidities: acne vulgaris, psoriasis, seborrhoeic dermatitis, excoriations, and folliculitis. We determined a point prevalence of hidradenitis suppurativa of 0.3%. Since we have examined the working population, the healthy worker effect, which could have led to underestimation of prevalence, cannot be ruled out. The point prevalence of 0.3% for employed people in Germany and a prevalence of 3.0% for inflammatory and non-inflammatory hidradenitis suppurativa-related lesions show that hidradenitis suppurativa is an important disease for the whole health system.

Entities:  

Keywords:  Atopy; Comorbidity; Epidemiology; Health care; Psoriasis

Mesh:

Year:  2020        PMID: 32322958      PMCID: PMC7864810          DOI: 10.1007/s00403-020-02065-2

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  25 in total

Review 1.  Hidradenitis suppurativa and metabolic syndrome - systematic review and adjusted meta-analysis.

Authors:  Kevin Phan; Olivia Charlton; Saxon D Smith
Journal:  Int J Dermatol       Date:  2019-05-31       Impact factor: 2.736

2.  High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa.

Authors:  Angelique Rondags; Kelsey R van Straalen; Suzanne Arends; Hessel H van der Zee; Errol P Prens; Anneke Spoorenberg; Barbara Horváth
Journal:  J Am Acad Dermatol       Date:  2018-12-14       Impact factor: 11.527

3.  Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): A cross-sectional reference study.

Authors:  Inge E Deckers; Ineke C Janse; Hessel H van der Zee; Tamar Nijsten; Jurr Boer; Barbara Horváth; Errol P Prens
Journal:  J Am Acad Dermatol       Date:  2016-07-21       Impact factor: 11.527

Review 4.  Hidradenitis Suppurativa: Disease Burden and Etiology in Skin of Color.

Authors:  Dylan E Lee; Ashley K Clark; Vivian Y Shi
Journal:  Dermatology       Date:  2018-03-01       Impact factor: 5.366

5.  The prevalence of hidradenitis suppurativa and its potential precursor lesions.

Authors:  G B Jemec; M Heidenheim; N H Nielsen
Journal:  J Am Acad Dermatol       Date:  1996-08       Impact factor: 11.527

6.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.

Authors:  C C Zouboulis; N Desai; L Emtestam; R E Hunger; D Ioannides; I Juhász; J Lapins; L Matusiak; E P Prens; J Revuz; S Schneider-Burrus; J C Szepietowski; H H van der Zee; G B E Jemec
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-01-30       Impact factor: 6.166

7.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.

Authors:  Jean E Revuz; Florence Canoui-Poitrine; Pierre Wolkenstein; Cedric Viallette; Germaine Gabison; Florence Pouget; Florence Poli; Ousmane Faye; Jean Claude Roujeau; Genevieve Bonnelye; Jean Jacques Grob; Sylvie Bastuji-Garin
Journal:  J Am Acad Dermatol       Date:  2008-10       Impact factor: 11.527

8.  Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study.

Authors:  J H Lee; H S Kwon; H M Jung; G M Kim; J M Bae
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-05-31       Impact factor: 6.166

9.  Demographic and clinical features of hidradenitis suppurativa in Korea.

Authors:  Ji Hoon Yang; Jungyoon Moon; Young Chul Kye; Kwang Joong Kim; Myeung Nam Kim; Young Suck Ro; Mi Youn Park; Hyo Hyun Ahn; Mi Woo Lee; Weon Ju Lee; Ju Hee Lee; Jee Bum Lee; Min Soo Jang; Yu Sung Choi; You Won Choi; Dae Hun Suh
Journal:  J Dermatol       Date:  2018-10-08       Impact factor: 4.005

10.  Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study.

Authors:  P Theut Riis; O B Pedersen; V Sigsgaard; C Erikstrup; H M Paarup; K R Nielsen; K S Burgdorf; H Hjalgrim; K Rostgaard; K Banasik; H Ullum; G B Jemec
Journal:  Br J Dermatol       Date:  2018-09-20       Impact factor: 9.302

View more
  1 in total

Review 1.  [Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa].

Authors:  N Kirsten; V Frings; G D Nikolakis; D Presser; M Goebeler; C C Zouboulis; M Augustin
Journal:  Hautarzt       Date:  2021-07-05       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.